RE: evolution in medicine!Management has been cautious in its research, development and final product production decision.
The preliminary production rate is 10,000 units per year with the possibility to increase to 100,000 units according to demand wihout major further investment. The manufacturer selling price will be $145 Cdn. Management has been able to bring this product to the market without dramatic stock dilution. The net profit margin will remain low at 10,000 rate on account of overhead cost etc. But if production increases the net margin will increase sharply, rewarding the patient investor